LITHIUM CITRATE
LOE ApproachingNDAORALSYRUP
Approved
Dec 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
LITHIUM CITRATE by Hikma is 12 clinical. First approved in 1980.
Drug data last refreshed 13h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Lithium citrate is an oral syrup formulation of lithium, a small-molecule mood stabilizer approved in 1980 for psychiatric indications. It works by modulating neurotransmitter activity in the central nervous system. The drug is indicated primarily for bipolar disorder and depression management.
$0.004BPart D
LOE ApproachingMature product with minimal Part D presence and significant generic competition; expect limited team expansion and focus on niche patient retention.
Mechanism of Action
12 CLINICAL. PHARMACOLOGY 12.1 Mechanism of Action The mechanism of action of lithium as a mood stabilizing agent is unknown. 12.3 Pharmacokinetics Absorption: After oral administration, lithium is reported to be completely absorbed in the upper gastrointestinal tract. Peak serum concentrations (T…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on LITHIUM CITRATE at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.